Accustem Sciences (ACUT) Non-Current Assets (2022 - 2026)
Accustem Sciences (ACUT) posted quarterly Non-Current Assets of $1.5 million for Q1 2026, up 1428471.43% year-over-year from N/an in Q1 2025, and little changed quarter-over-quarter from $1.5 million in Q4 2025.
Accustem Sciences (ACUT) Non-Current Assets (2022 - 2026) Analysis & Trends
Accustem Sciences (ACUT) has reported Non-Current Assets for 5 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 1428471.43% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $3.0 million (up 73411.39% YoY), while the FY2025 annual figure was $1.5 million, up 358751.67% from the prior year.
- Non-Current Assets steadied at $1.5 million in Q1 2026 per ACUT's latest filing, from $1.5 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.5 million in Q4 2025 and bottomed at $105.0 in Q1 2025.
- Historically, Non-Current Assets has averaged $204142.5 across 5 years, with a median of $5863.0 in 2023.
- Annual changes were most pronounced in 2025 — Non-Current Assets tumbled 96.66% — and 2026, when it soared 1428471.43%.
- Accustem Sciences' Non-Current Assets stood at $7678.0 in 2022, then tumbled by 47.28% to $4048.0 in 2023, then plunged by 89.67% to $418.0 in 2024, then soared by 358751.67% to $1.5 million in 2025, then changed by 0.0% to $1.5 million in 2026.
- Business Quant data shows ACUT's Non-Current Assets at $1.5 million in Q1 2026, $1.5 million in Q4 2025, and $105.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Accustem Sciences | 3.54 Mn | 3.52 Mn | - | 1.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.50 Mn |
| Dec 31, 2025 | 1.50 Mn |
| Mar 31, 2025 | 105.00 |
| Dec 31, 2024 | 418.00 |
| Sep 30, 2024 | 1,325.00 |
| Jun 30, 2024 | 2,233.00 |
| Mar 31, 2024 | 3,140.00 |
| Dec 31, 2023 | 4,048.00 |
| Sep 30, 2023 | 4,955.00 |
| Jun 30, 2023 | 5,863.00 |
| Mar 31, 2023 | 6,770.00 |
| Dec 31, 2022 | 7,678.00 |
| Sep 30, 2022 | 8,585.00 |
| Jun 30, 2022 | 9,492.00 |
| Mar 31, 2022 | 7,526.00 |